University of Southern California
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Southern California sits in the top decile of US sponsors by registered trial count (#55 of 15,742 sponsors by registered trial count).
University of Southern California: 617 sponsored US clinical trials, 97 recruiting.
University of Southern California sponsors 617 registered US clinical trials on ClinicalTrials.gov, 97 of them currently recruiting, and 361 completed. 31 of these trials are in Phase 3-4 (later-stage) and 173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 6 trials.
Top-decile sponsor footprint
University of Southern California ranks in the top decile of sponsors by registered trial count (#55 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
361 of 466 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
617 total, page 3 of 13
Evaluating Process of Change in Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for Depression
NCT06245096
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
NCT05644262
PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy
NCT06132087
Linezolid for Syphilis Pilot Study
NCT05548426
Alzheimer's Plasma Extension
NCT06416072
Community Genetic Navigation Engagement Specialists to Increase Knowledge About Colorectal Cancer Genetics in Hispanic/Latino/a Communities
NCT07276048
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
NCT04616248
Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
NCT05340309
Precision Performance Status Compared With ECOG Performance Status
NCT07082257
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
NCT05514990
Music Training and Child Development Study
NCT05502939
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
NCT05171972
Are Smokers Switching to Vaping at Lower Risk for Cancer? (Electronic Cigarettes and Cancer Risk)
NCT03750825
Platelet Rich Plasma in Hiatal Hernia Repair
NCT05023174
A Novel, Comprehensive Approach to Post-stroke Gait Rehabilitation
NCT04411303
Advancing Postmenopausal Preventive Therapy
NCT04103476
Efficacy of a Physical Therapy Intervention Targeting Sitting and Reaching for Young Children With Cerebral Palsy
NCT04230278
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
NCT04387084
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
NCT04315701
Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer
NCT04832763
Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)
NCT04876638
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
NCT03657641
Does Timing Matter? Supporting Play, Exploration, and Early Developmental Intervention
NCT03518736
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
NCT03344211
Oxandrolone Rotator Cuff Trial
NCT03091075
FID-007 in Treating Participants With Advanced Solid Tumors
NCT03537690
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
NCT03330821
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
NCT03257761
Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA
NCT03234556
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
NCT03092856
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
NCT02717156
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
NCT02935361
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
NCT02664883
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
NCT02495896
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
NCT02537548
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
NCT01802346
Cochlear Implantation and Social Outcomes
NCT07584837
Hearing Loss and Brain Health Study
NCT07288463
Energy Deficiency on Hormones in Contraceptive Users
NCT07651800
Impact of Risk Feedback on Behavioral Trajectories
NCT07657221
Early Intervention to Prevent Development of PTSD in Burn Survivors and Their Caregivers
NCT07656545
Ketamine HCl Prolonged Release Oral Tablets for CRPS
NCT06419985
Social Determinants of Health HCC Trial
NCT07568457
Methamphetamine Use Disorder Support in Heart Failure Pilot Study
NCT07211724
Caring for Dementia Caregivers in Ethnic Immigrant Communities
NCT07550075
Vascular Intervention Strategies Trial for Alzheimer's
NCT07447206
PhoRTE® Therapy Efficacy: In-Person Versus Telehealth
NCT06934265
Investigating the Evolutionary Impact of Metabolic Flexibility on Physical Activity-Dependent BDNF and Cognition: Insights From the Val66Met Polymorphism
NCT07218497
Feasibility and Safety of the Airway Exchange Broncholaryngoscope (AEBLScope)
NCT07033702
Influencer Marketing and Adolescent E-cigarette Use
NCT07420842
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 83 |
| Phase 2 | 90 |
| Phase 3 | 9 |
| Phase 4 | 22 |
Therapeutic Areas
What is open in the University of Southern California pipeline
97 recruiting of 617 indexed (16% open); 361 completed (59%).
Phase mix: 31 late (III/IV) vs 173 early (I/II) (early-phase heavy).
Top condition: Obesity (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Southern California: open-pipeline peers nationwide
Peers matched on 617 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of Southern California sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 617 trials (± recruiting share)
- Baylor College of Medicine · 616 trials · 15% recruiting
- US Department of Veterans Affairs · 632 trials · 0% recruiting
- University of Rochester · 636 trials · 15% recruiting
- Janssen Research & Development · 593 trials · 11% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Youngstown State University · 16% recruiting · 19 trials
- Roswell Park Cancer Institute · 16% recruiting · 365 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- University of Oregon · 16% recruiting · 63 trials
Related
What to do with this University of Southern California page
617 registered trials is a research-attention snapshot, not an endorsement of University of Southern California or any single study.
- 97 of University of Southern California's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of Southern California studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Southern California pipeline card: 617 registered trials from official public datasets.Report a data error.